AKBA Stock Data and Insider Activity
AKBA - Akebia Therapeutics, Inc. Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.
Chart and Financial Data provided by TradingView
Whale Activity

Recently reported position changes by institutional investors

Senate Trading

Recent trades by U.S. Senators

No data for this ticker
House Trading

Recent trades by U.S. Representatives

No data for this ticker
Insider Trading

Quarterly net insider trading by a company's directors and management

Corporate Flights

Flights by private jets registered to AKBA

No data for this ticker
Government Contracts

Federal grants, loans, and purchases. Click on a date for more info.

Date Agency Amount

2021-06-15 00:00:00

2021-06-15 00:00:00